Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Summary Background Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of adding pazopanib to paclitaxel for patients with platinum-resistant or platinum-refractory advanced ovarian canc...

Full description

Saved in:
Bibliographic details
Volume: 16
Main Author: Pignata, Sandro, Dr
Lorusso, Domenica, MD
Scambia, Giovanni, Prof
Sambataro, Daniela, MD
Tamberi, Stefano, MD
Cinieri, Saverio, MD
Mosconi, Anna M, MD
Orditura, Michele, MD
Brandes, Alba A, MD
Arcangeli, Valentina, MD
Panici, Pierluigi Beneditti, Prof
Pisano, Carmela, MD
Cecere, Sabrina C, MD
Di Napoli, Marilena, MD
Raspagliesi, Francesco, MD
Maltese, Giuseppa, MD
Salutari, Vanda, MD
Ricci, Caterina, MD
Daniele, Gennaro, MD
Piccirillo, Maria Carmela, MD
Di Maio, Massimo, MD
Gallo, Ciro, Prof
Perrone, Francesco, MD
Format: Journal Article
Language: English
Zielgruppe: Academic
Place of publication: NEW YORK Elsevier Ltd 2015
ELSEVIER SCIENCE INC
Elsevier B.V
published in: The lancet oncology Vol. 16; no. 5; pp. 561 - 568
Related: on behalf of MITO 11 investigators
MITO 11 Investigators
MITO 11 investigators
ORCID: 0000-0002-7939-3104
0000-0003-0981-0598
0000-0001-5360-1895
0000-0001-8906-3785
0000-0001-8953-1657
Data of publication: 2015
ISSN: 1470-2045
1474-5488
EISSN: 1474-5488
Discipline: Medicine
Subjects:
Online Access: available in Bonn?
Database: Web of Knowledge
Science Citation Index Expanded
Web of Science
Web of Science - Science Citation Index Expanded - 2015
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Academic OneFile (A&I only)
MEDLINE - Academic
Database information Databases - DBIS